Alzheimer's disease; amyloid beta 42; apolipoprotein E; cerebrospinal fluid; longitudinal; magnetic resonance imaging; mild cognitive impairment; positron emission tomography; subjective cognitive decline; tau; Amyloid beta-Peptides; Biomarkers; tau Proteins; Humans; Cross-Sectional Studies; Cognition; Alzheimer Disease/pathology; Cognitive Dysfunction/diagnosis; Cognitive Dysfunction; Epidemiology; Health Policy; Developmental Neuroscience; Neurology (clinical); Geriatrics and Gerontology; Cellular and Molecular Neuroscience; Psychiatry and Mental Health
Abstract :
[en] [en] INTRODUCTION: It is uncertain whether subjective cognitive decline (SCD) in individuals who seek medical help serves the identification of the initial symptomatic stage 2 of the Alzheimer's disease (AD) continuum.
METHODS: Cross-sectional and longitudinal data from the multicenter, memory clinic-based DELCODE study.
RESULTS: The SCD group showed slightly worse cognition as well as more subtle functional and behavioral symptoms than the control group (CO). SCD-A+ cases (39.3% of all SCD) showed greater hippocampal atrophy, lower cognitive and functional performance, and more behavioral symptoms than CO-A+. Amyloid concentration in the CSF had a greater effect on longitudinal cognitive decline in SCD than in the CO group.
DISCUSSION: Our data suggests that SCD serves the identification of stage 2 of the AD continuum and that stage 2, operationalized as SCD-A+, is associated with subtle, but extended impact of AD pathology in terms of neurodegeneration, symptoms and clinical progression.
Disciplines :
Neurology
Author, co-author :
Jessen, Frank ; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany
Wolfsgruber, Steffen; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Bonn, Germany
Kleineindam, Luca; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Bonn, Germany
Spottke, Annika; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurology, University of Bonn, Bonn, Germany
Altenstein, Slawek; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Neuropsychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany
Bartels, Claudia; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany
Berger, Moritz; Institute for Medical Biometry, University of Bonn, Bonn, Germany
Brosseron, Frederic; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Daamen, Marcel; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Radiology, University of Bonn, Bonn, Germany
Dichgans, Martin; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany ; Institute for Stroke and Dementia Research, Klinikum der Universität München, Munich, Germany
Dobisch, Laura; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute for Cognitive Neurology and Dementia Research, University of Magdeburg, Magdeburg, Germany
Ewers, Michael; Institute for Stroke and Dementia Research, Klinikum der Universität München, Munich, Germany
Fenski, Friederike; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany
Fliessbach, Klaus; Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Bonn, Germany
Freiesleben, Silka D; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany
Glanz, Wenzel; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute for Cognitive Neurology and Dementia Research, University of Magdeburg, Magdeburg, Germany
Görß, Doreen; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany ; Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany
Gürsel, Selim; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, München, Germany
Janowitz, Daniel; Institute for Stroke and Dementia Research, Klinikum der Universität München, Munich, Germany
Kilimann, Ingo; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany ; Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany
Kobeleva, Xenia; Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Bonn, Germany
Lohse, Andrea; Department of Neuropsychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany
Maier, Franziska; Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany
Metzger, Coraline; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute for Cognitive Neurology and Dementia Research, University of Magdeburg, Magdeburg, Germany
Munk, Matthias; Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
Preis, Lukas; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany
Sanzenbacher, Carolin; Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
Spruth, Eike; Department of Neuropsychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany
Rauchmann, Boris; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, München, Germany
Vukovich, Ruth; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany
Yakupov, Renat; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute for Cognitive Neurology and Dementia Research, University of Magdeburg, Magdeburg, Germany
Weyrauch, Anne-Sophie; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Bonn, Germany
Ziegler, Gabriel; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute for Cognitive Neurology and Dementia Research, University of Magdeburg, Magdeburg, Germany
Schmid, Matthias; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Institute for Medical Biometry, University of Bonn, Bonn, Germany
Laske, Christoph; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany ; German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
Perneczky, Robert; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany ; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, München, Germany
Schneider, Anja; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Bonn, Germany
Wiltfang, Jens; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany ; German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
Teipel, Stefan; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany ; Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany
Bürger, Katharina; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany ; Institute for Stroke and Dementia Research, Klinikum der Universität München, Munich, Germany
Priller, Josef; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Neuropsychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany
Peters, Oliver; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany
Ramirez, Alfredo; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany ; Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Bonn, Germany
Boecker, Henning; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Radiology, University of Bonn, Bonn, Germany
HENEKA, Michael ; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Bonn, Germany
Wagner, Michael; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany ; Department of Neurodegenerative Diseases and Gerontopsychiatry, University of Bonn, Bonn, Germany
Düzel, Emrah; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute for Cognitive Neurology and Dementia Research, University of Magdeburg, Magdeburg, Germany
The authors acknowledge the German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE), reference number BN012, and Life Molecular Imaging for Florbetaben PET. Open Access funding enabled and organized by Projekt DEAL.
van der Flier WM, Scheltens P. Amsterdam dementia cohort: Performing research to optimize care. J Alzheimers Dis. 2018;62:1091-1111.
Garcia-Ptacek S, Cavallin L, Kåreholt I, et al. Subjective cognitive impairment subjects in our clinical practice. Dement Geriatr Cogn Dis Extra. 2014;4:419-430.
Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014;10:844-852.
Slot RER, Sikkes SAM, Berkhof J, et al. Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. Alzheimers Dement. 2019;15:465-476.
Pike KE, Cavuoto MG, Li L, Wright BJ, Kinsella GJ. Subjective cognitive decline: Level of risk for future dementia and mild cognitive impairment, a meta-analysis of longitudinal studies. Neuropsychol Rev. 2021;https://doi.org/10.1007/s11065-021-09522-3. Epub ahead of print
Janssen O, Jansen WJ, Vos SJB, et al. Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimers Dement. 2022;18:1832-1845.https://doi.org/10.1002/alz.12512. Epub ahead of print
Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement (N Y). 2020;6:e12050.
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535-562.
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-194.
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on AgingAlzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011;7:270-279.
Jessen F, Spottke A, Boecker H, et al. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). Alzheimers Res Ther. 2018;10:15.
Molinuevo JL, Rabin LA, Amariglio R, et al. Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017;13:296-311.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on AgingAlzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
Miebach L, Wolfsgruber S, Polcher A, et al. Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. Alzheimers Res Ther. 2019;11:66.
Papp K V, Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: the PACC5. Alzheimers Dement. 2017;3:668-677.
Wolfsgruber S, Kleineidam L, Guski J, et al. Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology. 2020;95:e1134-e43.
Bertens D, Tijms BM, Scheltens P, Teunissen CE, Visser PJ. Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population. Alzheimers Res Ther. 2017;9:8.
Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341-355.
Fischl B, van der Kouwe A, Destrieux C. Automatically parcellating the human cerebral cortex. Cerebral Cortex. 2004;14:11-22.
Iglesias JE, Augustinack JC, Nguyen K, et al. A computational atlas of the hippocampal formation using ex vivo, ultra-high resolution MRI: application to adaptive segmentation of in vivo MRI. Neuroimage. 2015;115:117-137.
Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424-435.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B 1995;57:289-300.
Yeo I, Johnson R. A new family of power transformations to improve normality or symmetry. Biometrika. 2000;87:954-959.
Proust-Lima C, Dartigues JF, Jacqmin-Gadda H. Misuse of the linear mixed model when evaluating risk factors of cognitive decline. Am J Epidemiol. 2011;174:1077-1088.
Proust-Lima C, Philipps V, Liquet B. Estimation of extended mixed models using l atent classes and latent processes: the R package lcmm. J Stat Softw. 2017;78:1-56.
Snitz BE, Wang T, Cloonan YK, et al. Risk of progression from subjective cognitive decline to mild cognitive impairment: the role of study setting. Alzheimers Dement. 2018;14:734-742.
Wolfsgruber S, Polcher A, Koppara A, et al. Cerebrospinal fluid biomarkers and clinical progression in patients with subjective cognitive decline and mild cognitive impairment. J Alzheimers Dis. 2017;58:939-950.
Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1924-1938.
Sperling RA, Donohue MC, Raman R, et al. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. 2020;77:735-745.
Duits FH, Teunissen CE, Bouwman FH, et al. The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean? Alzheimers Dement. 2014;10:713-23.e2.
Jessen F, Amariglio RE, Buckley RF, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19:271-278.
Dubois B, Epelbaum S, Nyasse F, et al. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurol. 2018;17:335-346.
Vogel JW, Varga Dolezalova M, La Joie R, et al. Subjective cognitive decline and βamyloid burden predict cognitive change in healthy elderly. Neurology. 2017;89:2002-2009.
Petersen RC, Wiste HJ, Weigand SD, et al. NIA-AA Alzheimer's disease framework: clinical characterization of stages. Ann Neurol. 2021;89:1145-1156.
FDA's decision to approve new treatment for Alzheimer's disease. June 2021. (https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease)
